MS. BONNY LAUREN MOORE MD NPI 1902048051

NPI Details

MS. Bonny Lauren Moore, MD is a hematology and oncology internal medicine in Fredericksburg, VA with 17 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. MS. Bonny Lauren Moore, MD NPI is 1902048051. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

4501 EMPIRE CT
FREDERICKSBURG, VA
ZIP 22408-949
Phone: (540) 371-0079
Fax: (540) 656-2653

The NPI 1902048051 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Magnesium level (HCPCS:83735)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, bortezomib, not otherwise specified, 0.1 mg (HCPCS:J9044)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Phosphate level (HCPCS:84100)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Vitamin d-3 level (HCPCS:82306)
• Urinalysis, manual test (HCPCS:81002)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Unclassified drugs (HCPCS:J3490)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Collection of blood sample from implanted device (HCPCS:36591)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Application of on-body injector for under skin injection (HCPCS:96377)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Uric acid level, blood (HCPCS:84550)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Prealbumin (protein) level (HCPCS:84134)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Drawing of blood for a medical problem (HCPCS:99195)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Administration of influenza virus vaccine (HCPCS:G0008)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Injection, furosemide, up to 20 mg (HCPCS:J1940)
• Coronavirus vaccine 14 (HCPCS:91313)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Adm sarscov2 100mcg/0.5ml3rd (HCPCS:0013A)
• Injection of drug or substance into vein (HCPCS:96374)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus (HCPCS:87426)
• Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report (HCPCS:93000)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Fee covid-19 vac 14 res (HCPCS:0134A)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Stool analysis for blood, by peroxidase activity (HCPCS:82272)
• Transitional care management services for problem of high complexity (HCPCS:99496)

The enumeration date for this NPI number is 4/2/2009 and was last updated on 7/21/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.